Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 1,901–2,000 of 3,116
Wongcharoen, W., Krittayaphong, R., Buddhari, W., Kiatchoosakun, S., Sriwijitkamol, A., Wannachalee, T., & Phrommintikul, A. (2025) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2024.14 · Cited by 1
Tipping the Scales: Strategies to Improve Anti‐Obesity Medication Access and Affordability
Komé, A. M., Boykin, A. R., Johnson-Jennings, A., & Coviello, A. D. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70118 · Cited by 1
Bøg, M., Bojesen, A. B., Emerson, S. S., Ivkovic, M., Jenkins, N. C., Lübker, C., Mamdani, M., Padgett, T., Lf, V. G., Weeke, P., et al. (2026) · PharmacoEconomics · doi:10.1007/s40273-025-01580-2 · Cited by 1
“Definitions for MI, hospitalisation for unstable angina and stroke events from the SELECT trial have been published previously [8].”
Self-citationPursuing remission in type 2 diabetes: Competing strategies or complementary paths?
Koufakis, T., Sarafidis, P. A., Τσάπας, Α., & Doumas, M. N. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70212 · Cited by 2
“21 Lifestyle interventions, by contrast, improve risk factors but do not replicate these drug-specific protective mechanisms, which may explain the lack of mortality benefit despite favourable changes in body weight and metabolic profile.”
Biologics for cardiovascular diseases: from bench to bedside
Sun, X., Wang, X., Jia, R., Tang, J., Zeng, X. Y., Zhao, F., Zeng, F., Huang, N., Li, J., & Cui, K. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02673-w · Cited by 4
“For example, on the basis of the results of large randomized controlled trials, dulaglutide, 200 – 203 liraglutide, 186,204 – 206 and semaglutide 207 – 209 have been shown to reduce the risk of MACEs in patients with CVD. Notably, while initially demonstrated in patients with T2DM, recent landmark…”
Residual coronary atherosclerotic risk and low LDL-cholesterol in chronic coronary syndromes
Neglia, D., Pane, K., Occhipinti, M., Gori, C. D., Rocchiccioli, S., Ragusa, R., Cavaliere, C., Zanfardino, M., Prontera, C., Botto, N., et al. (2026) · European Heart Journal - Imaging Methods and Practice · doi:10.1093/ehjimp/qyag021 · Cited by 1
“22,49 Anti-inflammatory therapies 53 and modern glucose-lowering agents 54–55 offer promise even if the adequate strategies to reduce residual risk in patients with stable CAD and adverse cardiometabolic profile are still under debate.”
Lasik, L., & Ukleja-Sokołowska, N. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114658 · Cited by 1
“The SELECT trial demonstrated that semaglutide reduces the risk of cardiovascular events in patients with overweight or obesity and established cardiovascular disease, without type 2 diabetes [18].”
Smolderen, K. G. E., Mena‐Hurtado, C., Divino, V. M., Zhao, Z., Chen, Y., Boland, J., Chao, A., Song, J., Smolarz, B. G., Knop, F. K., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101521 · Cited by 2
“SELECT demonstrated that semaglutide 2.4 mg significantly reduced the risk of the 3-point composite MACE outcome of MI, stroke, or CV death (hazard ratio [HR]: 0.80; [95% confidence interval (CI) 0.72 – 0.90], p < 0.001) compared with placebo [6,7].”
InfluentialDrug treatment of chronic heart failure with reduced ejection fraction
Shamsi, A., & Sado, D. M. (2025) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2024.000050 · Cited by 2
Akwe, J. A., Fongeh, K., Jung, S. A., Hall, M. A. K., Patidar, V., & Shin, Y. M. (2025) · Cureus · doi:10.7759/cureus.91677 · Cited by 4
Mooradian, A. D. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00685-x · Cited by 1
Zhao, W., Niu, X., Zhou, X., Shi, R., & Zhou, X. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33885-4.00007-x · Cited by 1
Chen, Z., Cheng, R., Wang, H., & Hu, F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71083 · Cited by 2
Heart Failure with Preserved Ejection Fraction among Cancer Patients
Upshaw, J. N., & Golec, S. B. (2025) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-025-01136-9 · Cited by 1
Farkas, G. J., Solinsky, R. J., & Park, A. (2026) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2026.02.498 · Cited by 1
GLP-1R agonists: Full of hope, use with caution
Xu, Y., & Li, J. (2024) · The Innovation Medicine · doi:10.59717/j.xinn-med.2024.100086 · Cited by 1
Cocianni, D., Rizzi, J. G., Barbisan, D., Contessi, S., Perotto, M., Savonitto, G., Zocca, E., Brollo, E., Soranzo, E., Merlo, M., et al. (2025) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001742 · Cited by 1
Pharmacological therapy in the obese patient: is it only a matter of fat loss?
Borghi, C., & Bragagni, A. (2026) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suag029 · Cited by 1
Sancho-Haro, E. S., Muñoz-López, M., Baz-Valle, E., Villanueva-Tobaldo, C. V., Tornero-Aguilera, J. F., López-Gil, J. F., López‐Moreno, M., Martín-Rodríguez, A., & Clemente‐Suárez, V. J. (2026) · Pharmaceuticals · doi:10.3390/ph19060897 · Cited by 2
Zawadka, M., Taguiam, E., Lê, M., Sanjanwala, R., Liu, S., Shah, A. H., & Kunutsor, S. K. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70411 · Cited by 6
Pattern of semaglutide prescription in a real-world Canadian patient cohort
Farahvash, A., Lee, M. C. M., Jain, R., & Jaakkimainen, L. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.06.006 · Cited by 5
Thomas, P. E., Nielsen, S. F., Nordestgaard, B. G., & Kamstrup, P. R. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag106 · Cited by 1
Goldenberg, R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15588 · Cited by 3
Hayman, M. M. E., Jones, W., Aman, A., Ward, J., Anderson, J. J., Lyall, D. M., Pell, J. P., Sattar, N. A., Welsh, P. I., & Strawbridge, R. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16178 · Cited by 3
Stamouli, E., Trakatelli, C., Sarigianni, M., Kitsios, K., & Kotsis, V. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03239-4 · Cited by 3
“Participants were randomised 1:1 to subcutaneous semaglutide 2.4 mg once weekly or placebo, with escalation over 16 weeks to the target maintenance dose, with and a mean follow-up of 39.8 months [36].”
InfluentialMondoh, A., Contreras, F., Craig, H. C., Crotty, M., & le Roux, C. W. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100256 · Cited by 3
“The SELECT trial demonstrated a 20% reduction in major cardiovascular events, marking the first pharmacotherapy for obesity to show cardiovascular benefit independent of weight loss itself [29].”
Harris, M., Brown, J., & Renehan, A. G. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03355-8 · Cited by 1
“Impressive fi ndings from the STEP [24], SURMOUNT [25] and SELECT [16] trials have led to the licencing and widespread use of GLP-1/dual receptor agonists for the treatment of obesity.”
Faria, B. C., de Oliveira, K. M., Radulski, D. R., Stipp, M. C., Galindo, C. M., Pereira, G. S., Beltrame, O. C., Ceron, R., Ganzella, F. A. D. O., Dittrich, R. L., et al. (2024) · Pharmacological Research - Reports · doi:10.1016/j.prerep.2024.100019 · Cited by 1
Martines, G., Tomasicchio, G., Rotelli, M. T., & Fazio, M. D. (2025) · Frontiers in Surgery · doi:10.3389/fsurg.2025.1624455 · Cited by 2
Bayés‐Genís, A. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.05.022 · Cited by 1
Contractile effects of albiglutide in the human and mouse atrium
Jn, N., Jarikova, M., Kirchhefer, U., Hofmann, B., & Gergs, U. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1831742 · Cited by 1
Increasing walking capacity in patients with peripheral artery disease
Beckman, J. A., & Creager, M. A. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00574-4 · Cited by 1
GLP-1 Receptor Agonists: Therapeutic Potential and Emerging Concerns
Nowak, K., Łupina, K., Kalisz, A., Ilkiewicz, Ł., & Janczura, J. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00459-w · Cited by 2
Ruga, S., Matarese, E., Bava, R., Lombardi, C., Dimatteo, T., Miscio, L., Raponi, M., Giordano, A., Sansone, C., Liguori, G., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19081230 · Cited by 1
AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026)
Walsh, M. N., Køber, L., Sliwa, K. S., Adamo, M., Agarwal, A., Banerjee, A., Bozkurt, B., Čikeš, M., Damasceno, A., Desai, A. S., et al. (2026) · Global Heart · doi:10.5334/gh.1569 · Cited by 7
Emulated Effects of Glucagon-Like Peptide 1 Receptor Agonist Therapy in the General Population
Schrage, B., Lackner, M. K., Hoshiyar, A., de Lemos, J. A., Engström, G., Grossmann, E., Ittermann, T., Leistner, D., Lorenz, T., Lyngbakken, M. N., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.01.055 · Cited by 2
Olumuyide, E. O., Ariel, K., & Aneni, E. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02143-x · Cited by 1
Rico-Fontalvo, J. E., Reina, M., Soler, M. J., Unigarro-Palacios, M., Castañeda-González, J. P., Quintero, J. J., Raad-Sarabia, M., de Moraes, T. P., & Daza-Arnedo, R. (2024) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2024-0101pt · Cited by 4
Devitt, P., Moran, B., & O’Shea, D. (2024) · Springer eBooks · doi:10.1007/978-3-031-63310-2_2 · Cited by 1
Yevusiak, T., Weisman, A., Retnakaran, R. R., Wharton, S., Drucker, D. J., & Kramer, C. K. (2026) · PLoS ONE · doi:10.1371/journal.pone.0354237 · Cited by 1
“In clinical trials, semaglutide promoted mean weight loss of approximately −16.9% and had beneficial effects on blood pressure, glucose metabolism, inflammatory markers, and lipid profiles [9–13].”
InfluentialPlutzky, J., Bogdański, P., Colhoun, H. M., Dağdelen, S., Deanfield, J. E., Emerson, S. S., Hovingh, G. K., Kahn, S. E., Ekström, K., Latkovskis, G., et al. (2026) · Circulation · doi:10.1161/circulationaha.125.074482 · Cited by 4
“20,31 This pattern suggests that some semaglutide effects on hsCRP level may precede major changes in body weight or occur with minimal weight loss.”
Self-citationAbusnana, S., Sabbour, H. M., Afandi, B. O., Farghaly, M., Farooqi, M. H., Hafidh, K., Hassanein, M. M., Jabbar, A., Shehab, A., Kalimat, R., et al. (2026) · Vascular Health and Risk Management · doi:10.2147/vhrm.s579970 · Cited by 1
Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists
Tran-Duc, P. N., & Heo, K. (2025) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2025.5.e9 · Cited by 4
Elkind, M. S. V. (2026) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/cont.0000000000001705 · Cited by 1
Cardiorenal outcomes of weight loss interventions in people with CKD and type 2 diabetes
Wilkinson, T. J., Goldney, J., Yates, T. E., Henson, J. J., Zaccardi, F., Khunti, K., Webb, D. R., Papamargaritis, D., & Davies, M. J. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf258 · Cited by 3
“Randomized controlled trials (RCTs) have confirmed the efficacy of semaglutide, licensed for T2DM and obesity, on improving kidney function, metabolic markers, and cardiovascular morbidity and mortality in people with [14 , 15 ] and without [16 , 17 ] T2DM.”
InfluentialNot All Weight Loss Is Equal: Towards Muscle‐Preserving Therapies in Obesity
Abraham, J. D., Khan, M. S., & Anker, S. D. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70298 · Cited by 1
“The SELECT trial demonstrated that semaglutide for weight loss reduces cardiovascular risk, and the BELIEVE trial continued to observe the beneficial effects on glycemic control in those that were on semaglutide [3, 8].”
Obesity and Heart Failure: Introducing the Theme
Monitillo, F., Basile, P., & Lisco, G. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13040153 · Cited by 2
“…to people living with preexisting CV disease and overweight or obesity but without T2D—once-weekly 2.4 mg semaglutide (34-month exposure) lead to a slight reduction in the risk of composite HF endpoint ( − 18%), mostly driven by semaglutide protection against deaths due to CV causes [123].”
InfluentialIncretin-based therapies for obesity and disordered eating: optimising care in general practice
Atlantis, E. E., Wu, R., & Dixon, J. (2026) · Family Medicine and Community Health · doi:10.1136/fmch-2025-003622 · Cited by 2
Examining HbA1c in Frail Older Adults: A Linked Data Cohort Study
Meyerowitz‐Katz, G., McDonagh, J., William, S., John, R., Hng, T., McLean, M. P., Bul, M., Lindley, R. I., & Ferguson, C. (2026) · Australian Journal on Ageing · doi:10.1111/ajag.70163 · Cited by 1
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2582-5787 · Cited by 1
Ponnana, S. R., Surya, N., Presswalla, F., Parameswaran, G., Narang, Y., Zhang, T., Chen, Z., Dazard, J.-E., Sirasapalli, S. K., Sivanantham, K., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101543 · Cited by 1
“The SELECT trial was the first study that reported a 20 % relative reduction in MACE risk with weekly 2.4 mg Semaglutide therapy [3] However, Semaglutide is expensive and a recent study analyzed data from the Medical Expenditure Panel survey (2022) reported that drug-eligible low-income individuals…”
InfluentialAn Undergraduate Course on the Statistical Principles of Research Study Design
Kennedy‐Shaffer, L. (2025) · The American Statistician · doi:10.1080/00031305.2025.2509664 · Cited by 2
Expression and functional diversity of the glucagon-like peptide-1 receptor across tumor types
Alba, M. M., Lee, W. H., Lee, J. S. H., Lu, Z., Stiles, B. L., & Ligumsky, H. (2025) · Discover Oncology · doi:10.1007/s12672-025-04097-4 · Cited by 4
“Additionally, GLP-1 and its antagonist exendin [ 9– 39] have We found that the frequency of genetic alterations in GLP-1R across all cancer types is significantly lower than the mutation rates of other GPCRs involved in cancer, including constitutively activating thyroid-stimulating hormone (TSH)…”
Baptista, S. B., de Morais, G. P., Morais, L. A., Costa, J., Vinhas, H., Campos, G., Ferreira, P. C., Vale, N. C., Seixo, F., Santos, M. B., et al. (2025) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2025.03.006 · Cited by 2
Lassen, M. C. H., Skaarup, K. G., Vaduganathan, M., Ostrominski, J. W., Jensen, J. S., Biering‐Sørensen, T., & Johansen, N. D. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae224 · Cited by 1
Xie, J., Yang, Y., Chen, W., (45927), L. W., Weng, S., Lyu, Q., & Cao, G. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00722-7 · Cited by 1
Cardiovascular Prevention in Obese Patients Without Diabetes: Risk-based Strategies Are Needed
Ferreira, J. P., Neves, J. S., & Saraiva, F. A. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.12.002 · Cited by 1
Alali, M., Naveed, A. K., Alnounou, A., Alharami, M., & Nashed, B. (2026) · Cureus · doi:10.7759/cureus.109979 · Cited by 1
“…trial enrolling over 17,000 adults with obesity and established cardiovascular disease but without diabetes, demonstrated that once-weekly semaglutide reduced the risk of major adverse cardiovascular events by 20% compared with placebo, independent of the degree of weight loss achieved [14].”
Semaglutide Hype or Hope: Evidence-based Review in Diabesity
Gupta, S., Makkar, B. M., Kesavadev, J., & Kumar, A. M. V. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1439 · Cited by 1
Utilizing Semaglutide for Addressing Type-2 Diabetes and Obesity
Gupta, R., & Sharma, S. (2025) · Current Signal Transduction Therapy · doi:10.2174/0115743624346660250317013032 · Cited by 2
Understanding the Interplay Between Obesity and Cancer: From Mechanisms to Therapeutic Opportunities
Hwang, S., Kim, B., Yang, S., & Jeong, S. M. (2026) · Cancers · doi:10.3390/cancers18101620 · Cited by 1
“However, cancer outcome data from large cardiovascular outcome trials such as SELECT remain immature, and ongoing FDA monitoring of a medullary thyroid carcinoma signal means that cancer-specific safety endpoints should be prospectively assessed [126,128].”
HFpEF Without Obesity: Fallen Off the Radar?
Nelson, A. J., & Pagidipati, N. J. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.05.011 · Cited by 1
New Oral GLP-1 Receptor Agonists: Gliprons
Kim, C. (2025) · NeuroTrials · doi:10.65321/ntta.2025.002 · Cited by 1
Khan, I., Meenakshi, S., Abubakar, M., Kumar, N., Gaikwad, V. L., Rai, A., & Murti, K. (2026) · Endocrine · doi:10.1007/s12020-026-04686-5 · Cited by 2
“GLP-1R is expressed in vascular endothelial cells, cardiomyocytes, and immune cells, and its activation has been linked to improved endothelial function, increased NO bioavailability, and reduced ischemia-hyperperfusion injury and myocardial energy demand [187–192].”
Advances and Challenges in Holistic Treatment of Cardiometabolic Kidney Disease as One Entity
Bozkurt, B. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.10.002 · Cited by 2
MIR192 Upregulates GLP-1 Receptor and Improves Statin-Induced Impairment of Insulin SecretionPreprint
Kuang, Y., Locatelli, C. A. A., Qin, Y., Zhang, Y., Theusch, E., Muñoz, A. S., Sánchez, G., Lü, M., Nguyen, M.-A., Yalamanchili, T., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.18.643960 · Cited by 1
Weight control issues: perspectives in aesthetic medicine
Kruglova, L. S., & Вардановна, Т. А. (2024) · Medical alphabet · doi:10.33667/2078-5631-2024-25-8-12 · Cited by 1
Yang, G., Burgess, S., & Schooling, C. M. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04244-7 · Cited by 3
10-Year Excess Mortality After First-Time Non–ST-Segment Elevation Myocardial Infarction
Lauridsen, P., Thrane, P. G., Gyldenkerne, C., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102661 · Cited by 1
Harris, M., French, D., Clare, K., Harvie, M., Wilson, D. T., Brown, J., Jayne, D. G., & Renehan, A. G. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03356-7 · Cited by 1
“Furthermore, we did not explore the practical considerations of funding such a trial, including who should be responsible, and this is an opportunity for further research.”
BOHLER, H. C. L. (2024) · Nursing Clinics of North America · doi:10.1016/j.cnur.2024.08.005 · Cited by 3
McGinnis, T., McCallum, M., Pan, Z., Cunningham, C., Saxon, D. R., & Thomas, E. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09943-3 · Cited by 4
Chuang, S., Khetpal, V., Lu, F. Q., & Wu, W. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103304 · Cited by 1
Henriques, J. P., Weckwerth, A. V. B., Sant’Ana, A. C. P., Damante, C. A., Santos, C. F., & Negrato, C. A. (2026) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2026.06.008 · Cited by 5
Concomitant use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with heart failure
Khademi, R., & Shoar, S. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00319-y · Cited by 1
“In the SELECT trial, semaglutide reduced major adverse cardiovascular events in patients with overweight or obesity and established atherosclerotic cardiovascular disease without diabetes [16].”
Loizidis, G., & Summer, R. S. (2026) · Clinical Rheumatology · doi:10.1007/s10067-026-08212-w · Cited by 1
Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies
Bijoch, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15145358 · Cited by 6
“The SELECT trial subsequently demonstrated a 20% relative reduction in major adverse cardiovascular events with semaglutide 2.4 mg in patients with obesity but without diabetes [4], extending the rationale for these agents well beyond glycaemic and weight management.”
InfluentialPrado, B. S., Mazzotti, D. R., Franci, A., Baracioli, L., Barbado, K. R., Saretta, R., Filho, R. K., & Drager, L. F. (2026) · Annals of the American Thoracic Society · doi:10.1093/annalsats/aaoaf071 · Cited by 1
Effect of semaglutide on major cardiovascular events
BMJ Publishing Group Ltd (2024) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2024.000007 · Cited by 1
Ordemann, J., & Elbelt, U. (2025) · Herz · doi:10.1007/s00059-025-05319-9 · Cited by 1
Marani, A., Neri, E., Morea, E., Bertolla, D., Gualdi, G., Borghi, A., Conti, A., & Amerio, P. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15135126 · Cited by 3
“In large cardiovascular outcome trials, semaglutide significantly reduced major adverse cardiovascular events independently of baseline BMI and weight loss [13].”
Wang, J., Fan, Y., Dube, S., Benz, P. M., Dube, D. K., Sanger, J. M., & Sanger, J. W. (2024) · Cytoskeleton · doi:10.1002/cm.21950 · Cited by 1
Sriram, S., & Arnolda, L. (2026) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986261448034 · Cited by 1
“69,70 These benefits were observed despite only modest weight reduction within the trial population, with participants achieving a mean loss of approximately 9.8 kg during the first year of treatment.”
InfluentialPossible Adverse Effects (AEs) of Semaglutide (Ozempic) Administration for the Latest Investigation
Bando, H. (2024) · doi:10.36502/2024/droa.6189 · Cited by 6
Lee, S., Kim, M., Trott, M., Siskind, D. J., & Kim, J. H. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261456190 · Cited by 2
Li, L., Shui, D., Zhang, X., Tan, B., & Deng, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1854779 · Cited by 2
“Their principal value may therefore be to expand therapeutic options within the incretin fi eld, rather than to overcome the core gastrointestinal liabilities of GLP-1-based treatment (40).”
Navigating the benefits and harms of GLP-1 and GLP-1/GIP agonists in obesity
O'Connor, R. G. (2026) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2025.000039 · Cited by 2
Echeverría, C. E., Ahmed, M., Gao, J., Stewart, S. L., Nathoo, I., Debarba, L. K., Lafourcade, C., Ahmed, T., Shamieva, O., Perrier, T., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.03.729910 · Cited by 1
A two-timepoint framework for sensitive and specific single-cell activity screening
Ramirez, A., Kyzar, E. J., Rogerson, L., Berland, C., Rodriguez, E., Guerrero, J., Setara, R., Eisengart, M., Virkar, S., Hammond, L. A., et al. (2026) · Neuron · doi:10.1016/j.neuron.2026.05.026 · Cited by 1
Kuo, Y.-J., Chen, L.-F., Chen, Y., Chen, P., & Lin, H. Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094120 · Cited by 3
Xiao-yu, Z., Deng, C.-H., Zhong, J.-Y., Wu, Q., Chen, Q.-X., Gao, X.-Y., Xu, Y., Jiang, Z., Guo, M., & Teng, F. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104859 · Cited by 1
Shekouh, D., Behboodi, M., Varmazyar, M., Khodadadiyan, A., Jochin, P., & Bazrafshan drissi, H. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08500-z · Cited by 1
Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study
Krüger, N., Schneeweiß, S., & Wang, S. V. (2026) · BMJ · doi:10.1136/bmj-2026-100011 · Cited by 2
Gryglewska-Wawrzak, K., Kapłon‐Cieślicka, A., Pawlak, A., Tomaszuk−Kazberuk, A., Rubiś, P., Niedziela, J. T., & Bielecka-Dabrowa, A. M. (2025) · Pharmaceuticals · doi:10.3390/ph18111726 · Cited by 4
“GLP-1 RAs, such as semaglutide and liraglutide, have been shown to reduce MACE and improve various cardiovascular risk factors, including body mass, blood pressure, and lipid profiles [49–51].”
/ (2025) · Australian Prescriber · doi:10.18773/austprescr.2025.024 · Cited by 1
The Timeline of the Association Between Diabetes and Cardiovascular Diseases: A Narrative Review
Luca, S. A., Bungau, R. M., Lazăr, S., Herascu, A., Gaiţă, L., Avram, V. F., & Timar, B. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196877 · Cited by 1
Mediano, O., & Masa, J. F. (2025) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2025.03.009 · Cited by 3
The cardiometabolic triad: obesity, sleep-disordered breathing, and epicardial adipose tissue
Cacciapuoti, F., Carpinella, G., Sessa, F., Liguori, M., Casolaro, F., Russo, M., Verde, N., & Mauro, C. (2026) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.26.07120-6 · Cited by 1
Roy, A., Pabani, U. K., Kyriakou, A., & Elliott, M. K. (2026) · Cureus · doi:10.7759/cureus.117278
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
